Annis Gardner Whiting Capital Advisors LLC Cuts Stake in Novo Nordisk A/S (NYSE:NVO)

Annis Gardner Whiting Capital Advisors LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 23.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,130 shares of the company’s stock after selling 351 shares during the quarter. Annis Gardner Whiting Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $79,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Nuveen Asset Management LLC raised its holdings in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $158,657,000. Bank of America Corp DE raised its stake in shares of Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company’s stock worth $1,332,655,000 after acquiring an additional 1,165,955 shares in the last quarter. Northern Trust Corp lifted its position in Novo Nordisk A/S by 26.8% during the fourth quarter. Northern Trust Corp now owns 4,689,098 shares of the company’s stock valued at $403,356,000 after acquiring an additional 991,022 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Novo Nordisk A/S by 543.9% in the fourth quarter. Marshall Wace LLP now owns 1,167,498 shares of the company’s stock valued at $100,428,000 after acquiring an additional 986,195 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $47.20 on Wednesday. The stock has a market capitalization of $210.75 billion, a P/E ratio of 13.96, a P/E/G ratio of 1.48 and a beta of 0.63. The company’s fifty day moving average price is $68.43 and its 200 day moving average price is $72.20. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a 1 year low of $46.90 and a 1 year high of $139.74.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday. HSBC lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price target on the stock. in a research note on Thursday, July 31st. Finally, Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $93.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.